A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Acmopatide (CT-868), a Fully Biased GLP-1/GIP Receptor Agonist, in Adults With Type 1 Diabetes and Overweight or Obesity

OBJECTIVE: To evaluate the efficacy and safety of acmopatide, a signal-biased glucagon-like peptide 1/glucose-dependent insulinotropic polypeptide receptor agonist, in adults with type 1 diabetes (T1D) and overweight/obesity. RESEARCH DESIGN AND METHODS: In this phase 2, 16-week, randomized, double-blind, placebo-controlled, multicenter study, adults with T1D (HbA1c 7.0-10.0%; BMI ≥27 kg/m2) were randomized 1:1:1:1 to once-daily subcutaneous acmopatide (1.8, 4.1, or 6.6 mg) or volume-matched placebo. The primary end point was change from baseline (CFB) in HbA1c (%) at week 16; secondary end points included percent CFB in body weight and insulin dose. RESULTS: Overall, 111 participants were randomized (placebo n = 29, acmopatide 1.8 mg n = 27, 4.1 mg n = 28, 6.6 mg n = 27). Mean (SD) baseline HbA1c was 7.5% (0.6), and mean BMI was 34.3 (5.6) kg/m2. Acmopatide improved HbA1c (least squares [LS] mean CFB -0.4 to -0.6% vs. -0.3% with placebo; nominally significant placebo-adjusted difference for 4.1 mg: -0.3% [90% CI -0.6 to -0.1]; P = 0.020). HbA1c <7.0% was achieved by 55.6% of participants receiving acmopatide 4.1 mg vs. 33.3% receiving placebo. Acmopatide-treated participants demonstrated reductions in body weight (LS mean CFB -3.3 to -6.7% vs. 0.3% with placebo; all P < 0.01), total daily insulin dose (-3.4 to -14.9% more than placebo for acmopatide 4.1 and 6.6 mg), and mean systolic blood pressure (-3.1 to -8.4 mmHg vs. -3.3 mmHg with placebo). Adverse events were primarily gastrointestinal. No diabetic ketoacidosis (DKA) or severe hypoglycemia events occurred. CONCLUSIONS: In adults with T1D and overweight/obesity, acmopatide was associated with improved glycemic control and clinically meaningful weight loss without DKA or severe hypoglycemia events.

Authors

Institutions

Publication Details

Journal
Diabetes Care
Published
2026-10-28
DOI
https://doi.org/10.2337/dc26-1059
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Acmopatide (CT-868), a Fully Biased GLP-1/GIP Receptor Agonist, in Adults With Type 1 Diabetes and Overweight or Obesity

Thomas Blevins, Gabriele E. Sonnenberg, Halis Kaan Aktürk, David R. Liljenquist et al.
4 links
Diabetes Care
Diabetes Treatment and Management
article

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Acmopatide (CT-868), a Fully Biased GLP-1/GIP Receptor Agonist, in Adults With Type 1 Diabetes and Overweight or Obesity

Thomas Blevins, Gabriele E. Sonnenberg, Halis Kaan Aktürk, David R. Liljenquist, Anna Chang, Anuj Bhargava, Lori Gerard, Jean Park, Bruce Bode, Jeremy Pettus, Michelle Welch, Timothy Silleck Bailey, Mark S. Kipnes, Frances E. Broyles, Richard E. Pratley, Dan Lender, Heidi C. Shea, Brian J. Ulmer, Edward C. Jauch, Andrew Ahmann, Klara Rachel Klein, Athena Philis‐Tsimikas, Manu V. Chakravarthy, Joel Neutel, Kathryn Lucas, Jingtao Wu, Na Li, Eduardo Luna, Shafer Boeder, Acmopatide 004 Study Group*, Joseph Ravid
article en

Abstract

OBJECTIVE: To evaluate the efficacy and safety of acmopatide, a signal-biased glucagon-like peptide 1/glucose-dependent insulinotropic polypeptide receptor agonist, in adults with type 1 diabetes (T1D) and overweight/obesity. RESEARCH DESIGN AND METHODS: In this phase 2, 16-week, randomized, double-blind, placebo-controlled, multicenter study, adults with T1D (HbA1c 7.0-10.0%; BMI ≥27 kg/m2) were randomized 1:1:1:1 to once-daily subcutaneous acmopatide (1.8, 4.1, or 6.6 mg) or volume-matched placebo. The primary end point was change from baseline (CFB) in HbA1c (%) at week 16; secondary end points included percent CFB in body weight and insulin dose. RESULTS: Overall, 111 participants were randomized (placebo n = 29, acmopatide 1.8 mg n = 27, 4.1 mg n = 28, 6.6 mg n = 27). Mean (SD) baseline HbA1c was 7.5% (0.6), and mean BMI was 34.3 (5.6) kg/m2. Acmopatide improved HbA1c (least squares [LS] mean CFB -0.4 to -0.6% vs. -0.3% with placebo; nominally significant placebo-adjusted difference for 4.1 mg: -0.3% [90% CI -0.6 to -0.1]; P = 0.020). HbA1c <7.0% was achieved by 55.6% of participants receiving acmopatide 4.1 mg vs. 33.3% receiving placebo. Acmopatide-treated participants demonstrated reductions in body weight (LS mean CFB -3.3 to -6.7% vs. 0.3% with placebo; all P < 0.01), total daily insulin dose (-3.4 to -14.9% more than placebo for acmopatide 4.1 and 6.6 mg), and mean systolic blood pressure (-3.1 to -8.4 mmHg vs. -3.3 mmHg with placebo). Adverse events were primarily gastrointestinal. No diabetic ketoacidosis (DKA) or severe hypoglycemia events occurred. CONCLUSIONS: In adults with T1D and overweight/obesity, acmopatide was associated with improved glycemic control and clinically meaningful weight loss without DKA or severe hypoglycemia events.

Diabetes Care
University of North Carolina at Chapel Hill (US), F. Hoffmann-La Roche AG (CH), Genentech (US), AdventHealth Orlando (US), UC San Diego Health System (US), Roche (Canada) (CA)
Eli Lilly and Company, Sanofi, Dexcom, Novo Nordisk, Genentech
Good health and well-being
Openalex Percentile: Top 11%
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon